Vaqta Articles
Aventis Pasteur MSD to recall hep A vaccines
7 December 2001
Active Biotech regains ETEC vaccine from SB
8 August 2000
SmithKline Beecham Ground-Breaking In China
16 November 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Expanded US Use For SB's Havrix
3 July 1997
UK Industry Code Of Practice Review
2 July 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
UK Industry Code Of Practice In 1996
24 March 1997
New Products Drive Strong Growth At SB
24 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
SB's Twinrix Launched In Its First Market
20 January 1997
Korean Drug Cos In Alliances
6 January 1997
Global Branding Is A Must For Pharmaceuticals
12 August 1996
First Launch For Merieux' Hep A Vaccine
24 June 1996
New One-Dose Havrix For Children In UK
3 June 1996
First Vaqta Launch In Germany
8 April 1996
Merck's Vaqta
5 February 1996
SmithKline Beecham Meets Expectations In 1995 3rd Qtr
30 October 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
Interest Expenses, Currency Hit SB's Results
31 July 1995
Merck pipline report
3 July 1995
Vaccine News From ECCMID
3 April 1995
Havrix Gains Chinese Approval
20 March 1995
For SmithKline Beecham 1994 Was "Successful Year"
27 February 1995
SB's Havrix Approved In The USA
27 February 1995
EUROPEAN STOCK COMMENT
2 January 1995
Analysts Upgrade SmithKline Beecham
31 October 1994
SB Sales Jump 8%, Fuelled By New Drugs
24 October 1994
SmithKline Beecham On Adapting To Change
10 October 1994
Havrix Launched In Canada
12 September 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
PH II RESULTS OF PROSCAR BALDNESS TRIALS
25 April 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
HAVRIX BACKED BY US ADVISORY PANEL
14 February 1994
UK PRODUCT NEWS IN BRIEF
7 February 1994
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
CONNAUGHT, MERCK FROSST VACCINE DEAL
13 December 1993
PHARMA AWARD FOR SMITHKLINE
25 October 1993
EUROPEAN IMMUNOGLOBULIN SHORTAGE
9 August 1993
VAQTA HEP A VACCINE IS EFFECTIVE
19 July 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
MEDEVA ACQUIRES HEPATITIS A VACCINE
21 December 1992
GALLUP SURVEYS UK GPs ON HEPATITIS A
6 April 1992
GALLUP SURVEYS UK GPs ON HEPATITIS A
6 April 1992
UK DRUG STOCKS BULL RUN OVER?
10 February 1992
A REAL NEED FOR SB'S HAVRIX, MEETING HEARS
3 February 1992
SB HEP A VACCINE APPROVAL
20 January 1992
Showing 1-54 of 54 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
